In vivo RNAi delivery
Monday, 16 February, 2009
Invitrogen has launched its Invivofectamine delivery reagent, which enables siRNA experiments in vivo. As opposed to other offerings on the market, Invivofectamine delivery reagent can be injected in small volumes and without high pressure, minimising the potential of inconsistent results. It also provides extra stability to siRNA so the siRNA will arrive intact and ready to perform the selected knockdown. The reagent is non-viral and has minimal toxicity. Overall, these characteristics will enable researchers to more effectively optimize their siRNA experiments in vivo.
Invitrogen
www.invitrogen.com/invivornai
1500 Queensland women to help develop ovarian cancer screening test
Postmenopausal women between the ages of 50 and 74 with intact ovaries, and no prior history of...
A neuroscientist and biochemist's antiviral lightbulb moment
While studying how certain processes work inside the human brain, an Australian scientist...
Antimicrobial resistance in children rises globally — 100K+ samples reveal
Spanning 82 countries, there was an increase in every region between 2004 and 2022, with the...
